PGS is genetic screening. It is used to screen the health of embryos. PGS pre-implantation genetic screening and diagnosis is to perform biopsy on three days of fertilization (8 cell stage) or the fifth day of embryo (blastocyst stage) A single cell is used for whole-genome expansion.

What is PGS?
Preimplantation Genetic Screening (PGS) is mainly used for couples who have no history of genetic disease but who are at risk of chromosomal abnormalities. Before embryo implantation, PGS was used to analyze the chromosomes of early embryos. By examining the structure and number of 23 pairs of chromosomes of the embryo, it was judged whether the embryo had abnormal genetic material, so as to select healthy embryos for transplantation.

The clinical significance of
PGS PGS can screen out chromosomes with abnormal number and structure, and screen to identify transplantable embryos. The main clinical significance of PGS for chromosomal abnormalities:
· Screening and identification of embryos that can be transplanted
· Increase embryo implantation rate
· Reduce abortion rate
· Increase the chance of having a healthy fetus

Applicable crowd
Older women (age ≥35 years old)
Repeat spontaneous couples (More than 2 spontaneous abortions)
couples who have had children with chromosomal diseases. Couples who have
failed repeated transplants.

Serious male factors lead to infertility (severe oligozoospermia, etc.) According to statistics from authoritative institutions, there are an average of 8 couples of reproductive age in China 1 Facing difficulties in fertility, the infertility rate has climbed to 12.5% ​​-15%, close to the level of developed countries. The most serious is that this proportion is still rising. WHO experts estimate that China ’s infertility rate will climb to more than 20% in recent years.
More and more couples who are unable to conceive naturally choose IVF technology and have their own babies. Scientific research shows that a healthy embryo is the key to a successful pregnancy. However, 40-60% of embryos obtained by in vitro fertilization have chromosomal abnormalities, and the risk of chromosomal abnormalities increases with age. Therefore, pre-implantation genetic screening (PGS) technology is receiving more and more attention.

Clinical research data shows that PGS can reduce the miscarriage rate of pregnant women receiving assisted reproductive technology from 35.5% to 6.9%, while increasing the clinical pregnancy rate from 45.8% to 70.9% of traditional methods. According to the newly released research results, PGS can significantly improve various indicators of IVF.